Latest Intellectual Property News

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

BPH Global has completed its acquisition of Indonesian seaweed assets, establishing a wholly owned subsidiary and launching joint operations aimed at expanding seaweed cultivation and bio-stimulant product development across Asia.

Icetana Limited has announced a fully underwritten renounceable entitlement offer to raise approximately $2.65 million, aiming to bolster sales, marketing, and product development efforts. The offer, priced at $0.02 per new share, opens on February 3 and closes on February 14, 2025.

BPH Energy Limited's December 2024 quarterly report reveals strategic capital placements and investments in hydrogen and medical technology, alongside ongoing regulatory challenges with the PEP-11 permit.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.